ClinicalTrials.gg
TerminatedNCT06961370Updated Nov 4, 2026

A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

A Phase 1 interventional study of RO7669330 and Syfovre™ in Geographic Atrophy and Age-related Macular Degeneration, sponsored by Hoffmann-La Roche. Terminated at 17 sites in United States. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Treatment

Why this study was terminated
The study was terminated prematurely by the Sponsor due to observation of dose-limiting adverse events meeting the protocol-defined stopping criteria.
Updated Nov 4, 20261 site added1 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
27
Allocation
Randomized
Ages
55 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies in Geographic Atrophy by Hoffmann-La Roche — 2 open to participants now, 2 under way, none of them phase 3. Geographic Atrophy · Hoffmann-La Roche.

Enrollment
13th of 14
27 · median 144
Started
2025
the only one that year
Phase 1
4 of 16
none open now
Registered
15th of 16
by date

Among the 16 studies in Geographic Atrophy by Hoffmann-La Roche, this one is the 13th largest by enrollment of the 14 interventional ones that give a count, is the only one that started in 2025, is one of 4 in phase 1, and was the 15th registered.

Geographic Atrophy

188 studies on the registry are indexed under Geographic Atrophy; 52 are open to participants now.

Browse Geographic Atrophy studies →

Open to participants now

2 of the 16 studies in Geographic Atrophy by Hoffmann-La Roche are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 40 Geographic Atrophy studies recruiting now, 31 (78%) set no upper age limit and none (0%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 55 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Geographic Atrophy by Hoffmann-La Roche, or all of them as a file.
02

Study summary

The main purpose of this study is to assess the ocular and systemic safety and tolerability of RO7669330 in participants with GA secondary to AMD in at least one eye in Part 1, or both eyes in Part 2, after multiple unilateral intravitreal (IVT) doses.

03

Conditions studied

  • Geographic Atrophy
  • Age-related Macular Degeneration
04

Who can participate

Ages eligible
55 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adequately clear ocular media, adequate pupillary dilation, and fixation to allow acquisition of good quality fundus imaging
  • GA that resides completely within the fundus autofluorescence (FAF) imaging field
  • Presence of hyperautofluorescence of either banded or diffuse pattern adjacent to the GA area on FAF
  • Study eye has early treatment of diabetic retinopathy study (ETDRS) best-corrected visual acuity (BCVA) score as follows:
  • Part 1A: 19 to 48 letters, inclusively
  • Part 1B: > 19 letters
  • Part 2: ≥ 24 letters
  • Total GA lesion size must be as follows:
  • Parts 1A and 1B: ≥ 1.25 square millimeter (mm\^2) and ≤ 20 mm\^2 )
  • Part 2: ≥ 2.5 mm\^2 and ≤ 20 mm\^2

Exclusion criteria

Exclusion Criteria:

Ocular Exclusion Criteria for the Study Eye:

  • Aphakic or pseudophakic with intraocular lens outside of the capsular bag
  • Previous laser photocoagulation or IVT anti-vascular endothelial growth factor (VEGF) for CNV, diabetic macular edema (DME), retinal vein occlusion (RVO), or proliferative diabetic retinopathy
  • Active or history of CNV

Ocular Exclusion Criteria for the Non-Study Eye:

- Non-functioning non-study eye, defined as either: BCVA of hand motion or worse and/or no physical presence of eye

Ocular Exclusion Criteria for Both Eyes:

  • Macular atrophy in either eye due to causes other than AMD
  • Part 2: Evidence of prior or active CNV
  • Prior treatment with any approved therapy for GA (Syfovre, Izervay) in either eye for Part 1A and Part 2 ≤ 20 weeks prior to Day 1. For Part 1B, prior treatment with any approved therapy for GA (Syfovre, Izervay) in the study eye ≤ 20 weeks prior to Day 1
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    Part 1A: Multiple Ascending Dose (MAD)

    Participants will receive multiple doses of RO7669330 as IVT injections in the study eye with additional cohorts of participants receiving higher doses of RO7669330.

    Drug: RO7669330

  • Experimental
    Part 1B: Syfovre and Izervay

    Participants will receive either Syfovre, 15 milligrams (mg) or Izervay, 2 mg, as an IVT injection in the study eye.

    Drug: Syfovre™ · Drug: Izervay™

  • Experimental
    Part 2: RO7669330 vs Active Comparator (Syfovre or Izervay)

    Participants will receive RO7669330 (at two dose levels) or the active comparator (either Syfovre or Izervay), as an IVT injection in the study eye.

    Drug: RO7669330 · Drug: Syfovre™ · Drug: Izervay™

Interventions

  • DrugRO7669330

    RO7669330 will be administered as an IVT injection in the study eye per the schedule specified in the respective arms.

  • Syfovre™ will be administered as an IVT injection in the study eye per the schedule specified in the respective arms.

    Also known as: Pegcetacoplan injection

  • Izervay™ will be administered as an IVT injection in the study eye per the schedule specified in the respective arms.

    Also known as: Avacincaptad pegol IVT solution

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AEs)

    Time frame: Up to a maximum of 34 weeks

  2. Number of Participants With Abnormalities Recorded in Standard Ophthalmological Assessments

    The standard ophthalmological assessments that will be conducted may include the following: slit-lamp, indirect ophthalmology, intraocular pressure (IOP), best corrected visual acuity (BCVA), spectral domain optical coherence tomography (SD-OCT), fundus fluorescein angiography (FFA), and color fundus photography (CFP).

    Time frame: Up to a maximum of 34 weeks

Secondary outcomes

  1. Part 1A and Part 2: Ocular and Systemic Concentration of RO7669330

    Time frame: Up to a maximum of Week 24

07

Study locations

17 sites
  • Associated Retina Consultants - Phoenix - DocTrials - PPDS
    Phoenix, Arizona 85020-5505, United States
  • Barnet Dulaney Perkins Eye Center
    Sun City, Arizona 85351, United States
  • Retina - Vitreous Associates Medical Group, PC
    Beverly Hills, California 90211-1838, United States
  • Global Research Management
    Glendale, California 91204, United States
  • Retinal Consultants Medical Group Inc - Parkcenter Drive
    Sacramento, California 95825, United States
  • Southeast Retina Center
    Augusta, Georgia 30909, United States
  • Cumberland Valley Retina Consultants PC
    Hagerstown, Maryland 21740, United States
  • Deep Blue Retina Clinical Research
    Southaven, Mississippi 38671, United States
  • The Retina Institute
    St Louis, Missouri 63128, United States
  • Retina Northwest
    Portland, Oregon 97221, United States
  • Erie Retina Research
    Erie, Pennsylvania 16505, United States
  • Charles Retina Institute
    Germantown, Tennessee 38138, United States
  • Tennessee Retina PC
    Nashville, Tennessee 37203, United States
  • Austin Clinical Research, LLC
    Austin, Texas 78750, United States
  • Texas Retina Associates
    Dallas, Texas 75231, United States
  • Retina Consultants of Texas Westover Hills Retina Center
    San Antonio, Texas 78251, United States
  • Retina Consultants of Texas - (The Woodlands)
    The Woodlands, Texas 77384, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2025 to primary completion in Feb 2026, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2025
First posted
May 7, 2025
StartActual
Jul 16, 2025
Primary completionActual
Feb 3, 2026
CompletionActual
Mar 3, 2026
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Retina - Vitreous Associates Medical Group, PC · Beverly Hills, United States
Show 1 removed
  • Retina-Vitreous Associates Medical Group · Beverly Hills, United States
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    1 site added, 1 site removed
    Show site
    • Retina - Vitreous Associates Medical Group, PC · Beverly Hills, United States
    Show 1 removed
    • Retina-Vitreous Associates Medical Group · Beverly Hills, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06961370
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
May 7, 2025
Start date
Jul 16, 2025
Primary completion
Feb 3, 2026
Completion
Mar 3, 2026
Last update
Nov 4, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pegcetacoplan · Avacincaptad pegol

Start the discussion